Treatment-emergent cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii is associated with insertion sequence ISAba36 in the siderophore receptor pirA.

耐碳青霉烯鲍曼不动杆菌的治疗引起的头孢地洛耐药性与铁载体受体 pirA 中的插入序列 ISAba36 相关。

• 影响指数: 5.938
• 发表时间: 2024 Jul 9
• 来源期刊: Antimicrob Agents Chemother
• DOI: 10.1128/aac.00290-24
• PMID: 38809000
• 文章类型: Journal Article
• 中科院分区: Q1
• 方向: 医学
• 作者列表: Huang E,Thompson RN,Moon SH,Keck JM,Lowry MS,Melero J,Jun S-R,Rosenbaum ER,Dare RK

关键词: Acinetobacter baumannii; ISAba36; OXA-72; carbapenem resistance; cefiderocol; sulbactam-durlobactam

Mesh: Acinetobacter baumannii / drug effects genetics; Cefiderocol; Anti-Bacterial Agents / pharmacology; Humans; Cephalosporins / pharmacology; Acinetobacter Infections / drug therapy microbiology; Microbial Sensitivity Tests; Carbapenems / pharmacology; Receptors, Cell Surface / genetics metabolism; Sulbactam / pharmacology; Male; Drug Resistance, Multiple, Bacterial / genetics; Azabicyclo Compounds / pharmacology; DNA Transposable Elements / genetics; Bacterial Outer Membrane Proteins

Abstract

We report the emergence of cefiderocol resistance in a blaOXA-72 carbapenem-resistant Acinetobacter baumannii isolate from a sacral decubitus ulcer. Cefiderocol was initially used; however, a newly approved sulbactam-durlobactam therapy with source control and flap coverage was successful in treating the infection. Laboratory investigation revealed cefiderocol resistance mediated by ISAba36 insertion into the siderophore receptor pirA.

摘要

我们报告了从骶褥疮溃疡中分离出的对blaOXA-72碳青霉烯耐药的鲍曼不动杆菌对头孢地洛的耐药性。最初使用头孢地洛；然而，新批准的舒巴坦-durlobactam治疗与源控制和皮瓣覆盖成功治疗感染。实验室研究显示，通过将ISAba36插入铁载体受体pirA介导的头孢地洛耐药性。